Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)

NCT05601882 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05601882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05601882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
November 28, 2022
Completion date
August 8, 2024
Enrollment
920 (actual)
Sites
257

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis